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Abstract
Nature continues to produce a great wealth of natural molecules endowed with cyto-
toxic activity toward a large panel of tumor cells. Some of these molecules are used in 
chemotherapy, and others have shown great anti-tumor and anti-metastatic potential 
in preclinical trials. This review discusses some examples of these molecules that have 
been studied in our laboratory and others. We report a differential cytotoxic activity of 
some monoterpenes (carvacrol, tymol, carveol, carvone, and isopulegol) against a panel 
of tumor cell lines. The carvacrol was the most cytotoxic molecule both in vitro and in vivo 
as demonstrated by preclinical studies using the DBA2/P815 mice model. On the other 
hand, polyphenols were also studied with respect to their cytotoxic effects. Interestingly, 
these compounds showed a prominent cytotoxic activity toward a panel of cancer cells 
with differential molecular mechanisms. In addition, we report a very strong antitumor 
efficacy of artemisinin, a sesquiterpen lactone from Artemisia annua, together with an 
antimetastatic potential as demonstrated by preclinical experiments. Furthermore, some 
of the molecular mechanisms involved in these effects are described.
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1. Introduction
Natural drugs have formed the basis of traditional medicine systems that have been used for 
centuries by different cultures [1]. An immense number of these natural sources and their 
isolated components have demonstrated beneficial therapeutic effects, such as anticancer, 
antioxidant, immunomodulatory, antimicrobial, and anti-inflammatory properties [2, 3]. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Studies reported that plant-derived drugs represent about 25% of the American prescription 
drug market [4]. Also, natural products play an important role in the health care of 20% of 
the world’s people who mainly reside in developed countries and 119 chemicals compounds, 
derived from 90 plant species, can be considered as important drugs in many countries [5]. 
Based on a recent review, from 79 Food and Drug Administration anticancer and antivi-
ral approved drugs from 1983 to 2002, 9 of them were isolated directly from plants and 21 
among them were natural-products-based drug. Furthermore, between 39 conventional anti-
cancer molecules, 13 of them were derived on a pharmacophore obtained from natural drugs 
[5, 6]. Actually, nature continues to be an attractive source of new molecules discovery due 
to important chemical diversity of the thousands of plant, animal, marine organisms, and 
micro-organism species. Today, about 60% of drugs are of natural origin [7] (Tables 1–3).
Several molecules used as conventional chemotherapy are of natural origin. Some of these 
molecules and their use are described in Tables 2 and 3.
Drug Utilization Mechanism of action Source
Aspirine Analgesic, anti-inflammatory, 
anti-pyrtic
Inhibition of cyclo-oxygenase Plant
Atropine Pupil dilatator Anti-cholinergic on muscarinic 
receptors
Plant
Cafeine Stimulating Antagonist of adenosine receptors Plant
Codeine Analgesic, anti-tussive Antagonist of opoide receptors Plant
Digoxine Cardiotonic Inhibition of membrane pump N+/
K+ ATPase
Plant
Eugenol Touth pain Reduction of sensorial nerve 
excitability
Plant
Morphine Analgesic Antagonist of opoide receptors Plant
Pilocarpine Glaucoma Antagonist of muscarinic receptors Plant
Quinine Prophylaxis of malaria Inhibition of protein synthesis Plant
Taxol Anticancer Antimitotic Plant
Penicilline Antibiotic Inhibition of cell membrane Micro-organism
Tatracycline Antibiotic Inhibition of protein synthesis Micro-organism
Cyclosporine A Immunosuppressor Inhibition of lymphocytes T 
proliferation
Micro-organism
Aurantosides Antifungal Inhibition of tubulin  
polymerization
Marine organism
Spongistatine 1 Antifungal Inhibition of tubulin  
polymerization
Marine organism
Manoalide Analgesic, anti-inflammatory Inhibition of phospholipase A2 Marine organism
Table 1. Some natural drugs derived from plants, micro-organisms, or marine organisms [8].
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2. Phytotherapy and cancer
2.1. Generalities
There is a numerous plants involved in the prevention and/or treatment of cancer. As for 
other diseases, many anticancer drugs are derived from plants (Table 4). Studies reported 
that more than 200 drugs are of herbal origin. The vinca-alcaloids and the taxans are the main 
groups, which occupy an important place in anticancer chemotherapy.
2.2. Examples of natural products with important cytotoxic activity
2.2.1. Cytotoxic activity of some natural monoterpenes
The chemical composition of plant-extracts is known for being very rich and diversified. 
Thus, a single extract may contain more than hundreds of interactive biomolecules [9]. 
Therefore, finding and discovering those responsible for the biological Activity become 
essential. Many monoterpenes, such as eugenol, have been described in the literature to have 
Drug Utilization Mechanism of action
Citarabine Leukemia, lymphoma Inhibition of DNA synthesis
Bryostatine 1 Experimental phase Activation of protein kinase C
Dolastatine 10 Experimental phase Inhibition of microtubules and pro-apoptotic effect
Ecteinascidine 743 Experimental phase Alkylation of DNA
Aplidine Experimental phase Inhibition cell cycle progression
Halicondrine B Experimental phase Interaction with tubuline
Discodermolide Experimental phase Stabilization of tubuline
Cryptophycine Experimental phase Hyperphosphorylation of Bcl-2
Table 3. Some anticancer drugs derived from marine organisms [8].
Drug Utilization
Actinomycine Germinale cells tumor, sarcoma
Bléomycine Cervix cancer, Germinale cells tumor, and neck
Daunomycine Leukemia
Doxorubicine Lymphoma, breast, lung and ovarian cancer, sarcoma
Epirubicine Breast cancer
Idarubicine Leukemia and breast cancer
Mitomycine C Colorectal, gastric, anal, and lung cancer
Streptozocine Gastric and endocrine tumors
Table 2. Some anticancer drugs derived from micro-organisms [8].
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a wide range of important biological activities [10]; it possesses in vitro and in vivo antiviral 
activity against human herpesvirus [11]. Carvone promoted protection of 75–87.5% against con-
vulsions at 300–400 mg/kg [12]. Isopulegol and carvone showed significant bactericidal and 
fungicidal activities [13]. Also, the combination of these molecules between them or with con-
ventional molecules could have a synergistic effect [14, 15]. Furthermore, carvacrol, extract of 
thyme essential oil, is one of natural products with important biological activities. It has been 
reported to have an important antitumor effect [9, 16]. Here, we present a summary of our find-
ings [17] on the cytotoxic activity as well as their molecular mechanisms of six natural monoter-
penes compounds (carvacrol, thymol, carveol, carvone, eugenol, and isopulegol).
2.2.1.1. In vitro cytotoxic effect of the products against a panel of target cells
The antitumor activity of the products was evaluated against the following five tumor cell lines: 
P-815, K-562, CEM, MCF-7, and MCF-7 resistant to gemcetabine (MCF-7-gem). The results are 
summarized in Figure 1, which shows that the cytotoxic effect depends on the nature of the 
products as well as on the target cell lines. In general, the effect of the products is dose-depen-
dent. Moreover, the cytotoxic activity of carvacrol, thymol, carveol, carvone, eugenol, and 
isopulegol is more important against P-815 and CEM tumor cell lines compared to the other 
tested cell lines. The carvacrol is the most cytotoxic compared to other compounds. Against 
P-815, K-562 and CEM cancer cell lines, eugenol, carveol, and carvone exhibit also a strong 
cytotoxic activity. The IC
50
 values are ranging from 0.09 to 0.24 μM (Table 5). Nevertheless, 
those compounds showed a less effect toward MCF-7 and very lowest one against MCF-7-gem 
cancer cell lines as demonstrated by the IC
50
 values ranging from 0.26 to 0.87 μM. Comparing 
the activity of thymol and isopulegol on the tumor cell lines studied, it shows that P-815 is the 
most sensitive with an IC
50
 = 0.15 and 0.09 μM, respectively. Importantly, acquired resistance 
to gemcetabine by MCF-7 cell line was linked with a development of resistance to thymol, 
carveol, carvone, and eugenol but not to isopulegol or carvacrol (Table 5).
2.2.1.2. Synergy
Our results demonstrate that the combination of natural monoterpene with MTX or Cis 
showed a synergistic effect at used concentrations (IC
20
) of each tested molecules (monoter-
penes, cisplatine, and methotrexate). The interactions between these molecules exhibit a cell 
lysis ranging between 53 and 62%. Furthermore, a slight cytotoxicity was shown after the 
combinations between monoterpene-cisplatin and monoterpene-methotrexate (Table 6).
Drugs Utilization
Vincristine Leukemia, lymphoma, breast cancer, and lung cancer
Vinblastine Lymphoma, kidney cancer, germinal cells cancer, and breast cancer
Paclitaxel Breast cancer, ovarian, lung, and d’ovaire, de poumon, bladder, and neck cancer
Docetaxel Breast and lung cancer
Topotecan Ovarian and lung cancer
Irinotecan Colorectal and lung cancer
Table 4. Anticancer drugs derived from plants [8].
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Figure 1. Cytotoxic effect of carvacrol (A), thymol (B), carveol (C), carvone (D), eugenol (E) and isopulegol (F) against 
different tumor cell lines: P815 (♦), CEM (◾), K562 (_), MCF-7 (▴) and MCF-7 gem (*).
Product P815 CEM K-562 MCF-7 MCF-7/gem
Carvacrol 0.067 0.042 0.067 0.125 0.067
Thymol 0.15 0.31 0.44 0.48 —
Carveol 0.11 0.11 0.13 0.26 0.45
Carvone 0.16 0.11 0.17 0.63 0.91
Eugenol 0.10 0.09 0.24 0.41 0.87
Isopulegol 0.09 0.11 0.13 — 0.25
Table 5. IC
50
 (μM) of the tested monoterpenes against different target cell lines.
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2.2.1.3. Effect of carvacrol, thymol, carveol, carvone, eugenol, and isopulego on the cell cycle 
progression
At the molecular level, carveol- and carvacrol treatment-induced cell cycle arrest in S phase. 
Nevertheless, thymol and isopulegol stopped it in G0/G1 phase. Regarding the eugenol and 
carvone, they have no effect cell cycle progression (Figure 2).
2.2.1.4. In vivo antitumor effect of carvacrol
Our experimental model was based on the use of the P-815 tumor-bearing DBA-2 mice 
to investigate the cell-killing induced by carvacrol. Experiments were carried out by oral 
administration (gavage) of carvacrol dissolved in vegetal oil to 6- to 8-week-old DbA-2/6 mice 
(6 mice for each group) (Orleans, France) weighting 18–22 g for 7 days. The tumor volume was 
measured for up to 30 days. The tumor volume at day n, (Tvn) was calculated using the for-
mula: Tv = (l × W2)/2, where l equals the length of the tumor and W the width, as described 
by Yoshikawa [18]. Interestingly, during the first 18 days, there was no statistical difference 
(p < 0.94) in the volumes of the tumors in all the groups of mice, including the control group 
(0.4–0.5 ± 0.1 cm3). Nevertheless, after 18 days, the tumor volume was reduced for the treated 
groups; this decrease occurred more rapidly in the group “C” who received 100 mg/kg/day 
than the group “B” treated with 50 mg/kg/day (p < 0.05 at day 21th). Compared to untreated 
group, the tumor volume increased quickly reaching 1.5 cm3 at 23rd day. Furthermore 
and importantly, the tumor volume reduction was accompanied by a notable increase of 
mice survival (Figure 3). The antitumor activity of carvacrol has not been has not been 
Combination Fa CI
C-MTX 54.9 0.17
C-Cis 56.6 0.01
T-MTX 61 0.14
T-Cis 57.6 0.01
Cl-MTX 53.3 0.17
Cl-Cis 57.9 0.01
Cn-MTX 51.2 0.17
Cn-Cis 58.5 0.01
E-MTX 58.6 0.15
E-Cis 55.9 0.01
I-MTX 58.5 0.15
I-Cis 62.3 0.01
Table 6. Affected fraction (Fa) and combination index (CI) of molecule combinations.
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widely  discussed in the literature. At the best of our knowledge, this is the first study that 
reported the oral  administration of carvacrol for successive 7 days significant decrease tumor 
volume, body weight loss, and delayed mortality (data not shown). These results corroborate 
those published by Karkabounas who demonstrated that carvacrol exhibited 30% reduction 
of 3,4-benzopyrene carcinogenic activity in vivo [19].
Studies were carried out by gavage of carvacrol dissolved in vegetable oil to mice (6–8 week-
old) for 7 days. Group “A” (untreated) treated with 100 μl/day of vegetal oil only. Groups 
“B” and “C” received 50 and 100 mg/kg/day of carvacrol dissolved in 100 μl of vegetal oil, 
respectively. Mice were weighted and the tumor volume was calculated by measurement of 
the width (W) and the length (l) for three times a week up to day 30. The tumor volume at day 
n (TVn) was measured using the following formula: TV = (l × W2)/2. The experiments are the 
mean ± SEM of two tests.
2.2.1.5. Discussion
Monoterpenes (carvacrol, thymol, carveol, carvone, eugenol, and isopulegol) have been found 
to exert antitumor effect. In fact, eugenol was described to exhibit cell death by apoptosis in 
Figure 2. Effect of the tested products on cell cycle progression. The samples were analyzed using a FACStar plus flow 
cytometer and the WinMDI software. Results are the mean ± SEM of three tests. (A) Carvacrol, (B) thymol, (C) carveol, 
(D) carvone, (E) eugenol, and (F) isopulegol.
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mastocyte [20] and melanoma cells [21]. Also, it has been demonstrated not to be mutagenic 
neither carcinogenic [22]. Carveol has chemopreventive activity against mammary cancer 
when fed during the initiation phase [23]. Carvone prevents chemically induced lung and for 
stomach carcinoma development [24]. Carvacrol and thymol significantly reduced the level of 
DNA damage induced in K-562 cells by the strong oxidant H
2
O
2
 [25]. Furthermore, carvacrol 
has an important in vitro antitumor effect against tumor cell lines like Hep-2 [26] and A-549 
[16, 27]. As shown in Table 5, the monoterpenes studied induced a differential cytotoxic activ-
ity against a panel of tumor cell lines. P-815 and CEM cell lines are the most sensitive targets to 
all tested molecules. Although the effects of these products are dose-dependent, the carvacrol 
is the most cytotoxic molecule as revealed by the IC
50
 values (Table 5). Importantly, unlike 
isopulegol and carvacrol, the acquired resistance to gemcitabine by MCF-7 tumor cell line 
was associated with a resistance to thymol, carveol, and carvone. Taken together, these results 
suggest that these compounds could have a similar pathway. The differential sensitivity of 
the studied monoterpenes toward MCF-7 and MCF-7-gem could be linked to the expression 
level of ribonucleotide reductase subunit R1 [28]. Furthermore, the cell cycle analysis showed 
that carveol- and carvacrol treatment-induced cell cycle arrest in S phase when thymol and 
isopulegol stopped it in G0/G1 phase. Nevertheless, the eugenol and carvone have no effect 
cell cycle progression. These results suggest that the molecular  mechanistic pathway of the 
cytotoxicity exhibited by those molecules is more complicated and is not related only with 
the cell cycle. It was reported that monoterpenes decreased expression of cyclin-dependent 
kinase cdk4, cyclin D1, and cdk2 and increased expression of cyclin E and cdk inhibitor p21 
[29]. Furthermore, geraniol, farnesol, and isoprenoids perillyl alcohol exhibited a G0/G1 cell 
cycle arrest by increasing in the expression level of p27 (Kip1) and the cyclin kinase inhibi-
tor proteins p21 (Cip1) and a decreasing in cyclin B1, cyclin A, and cyclin-dependent kinase 
(Cdk2) expression [14]. Interestingly, our results demonstrate that the interaction of tested 
monoterpenes at lowest concentration (IC
20
) with the conventional anticancer molecules (cis-
platine and methotrexate) exhibited a synergistic activity (Table 6). Thus, this combination 
may reduce the toxicity of the conventional chemotherapy drugs by reducing their doses. 
Figure 3. In vivo antitumor effect of carvacrol.
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These results are supported by previous findings reporting that when combined to isopren-
oids perillyl alcohol, farnesol, and geraniol showed an additive antiproliferative activity 
against the human pancreatic cancer cell line MIA PaCa-2 [14]. Also, Chander et al. reported 
that in chemotherapy of breast tumors, the combination of limonene, natural monoterpene, 
and 4-hydroxyandrostenedione, inhibitor of aromatase, was more effective than each drug 
used alone [30]. Interestingly, in our study, we reported a synergistic effect and not an addi-
tive one suggesting that only low doses of each monoterpene combined with tolerable low 
doses of methotrexate or cisplatine (IC
20
) showed an important effect (60% lysis).
2.2.2. Polyphenols: a potent cytotoxic molecules
Natural polyphenols have received increasing interest in the human health due to their benefit 
effects against several diseases attributed particularly to their antioxidant activity [31]. Beside 
their well-known and effective antioxidant activity [32, 33], several polyphenols shown a high 
cytotoxic effect against cancer cell lines through targeting cellular and molecular processes 
involved in cancer progression and metastasis. The antitumor potential of these active ingre-
dients is due to their effect as modulators of oxidative stress [34], apoptosis inducers [35] cell 
proliferation inhibitor [36], tumor cell cycle blockers [37], and angiogenesis/metastasis sup-
pressors [38]. These bioactive compounds have shown promising antitumor properties in both 
in vitro and in vivo interventions [39, 40]. These structural variations may be responsible for 
their various health benefits, including antioxidant [41], and anti-proliferative mechanisms, 
as well as regulation of key signaling protein and enzyme functions [42], and as promising 
immunostimulating effect on normal immune cells [43]. The relationship among natural poly-
phenols, antitumor activity, and cancer was identified by various studies on the ability of these 
compounds to act as cancer chemopreventive and/or chemotherapeutic agents [44]. In this 
purpose, a variety of natural polyphenols have been identified to interfere with carcinogenesis 
particularly through apoptosis induction and the modulation of oxidative stress [45, 46].
2.2.2.1. Polyphenols and apoptosis induction
Large number of studies has focused on the ability to introduce apoptosis on cancer therapy 
under cellular control conditions [47, 48]. The intrinsic and extrinsic molecular pathways 
involved in the regulation of the apoptotic process have recently been evaluated and give 
promising results. Several proapototic receptors have been selectively developed activating 
the intrinsic pathway, particularly including the antiapoptotic proteins, the Bcl-2 family pro-
teins, and the p53 signaling pathways [49–51]. In this purpose, polyphenols could inhibit tumor 
cell  proliferation via the programmed cell death (apoptosis) using both intrinsic and extrinsic 
cell pathways. As reported, polyphenols such as EGCG: (−)-epigallocatechin-3-gallate, resve-
ratrol, naringenin, quercetin, hydroxytyrosol, and curcumin, through different intrinsic sig-
naling pathways from mitochondrial intermembrane space, may inhibit NF-κB-dependent 
signal related to proliferation and survival [52], cause cell cycle arrest through upregulation 
of p53 [53], stabilize and activate the tumor suppressor gene p53 [54], and downregulate the 
expression of Bcl-2, and Bcl-XL anti-death proteins, favoring apoptosis induction via the acti-
vation of multiple caspases activity and cytochrome-c (cyt-c) [55, 56]. These polyphenols have 
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been shown to promote apoptosis in different cancers particularly breast, lung, prostate, leu-
kemia, colon, cervical, or melanoma [57, 58]. In breast cancer cells, naringenin demonstrated 
anti-estrogenic activity in estrogen-rich status and estrogenic activity in estrogen-deficient 
status [59]. Additionally, few early studies suggested that gavage of polyphenols in green 
tea (EGCG), even at low doses, prevented colon carcinogenesis by inhibiting metastasis and 
angiogenesis through apoptosis induction [60]. Few years ago, our research group has pub-
lished an article [61] on natural polyphenols extracted from olive mill waste (OMW) and their 
implication in anticancer activity, where the in vitro cytotoxic and apoptotic assays involving 
several phenolic compounds found in those specific phenolic extracts (particularly including, 
quercetin, naringenin, apigenin, hydroxytyrosol, oleuropein, and its derivatives) have been 
discussed. The in vitro cytotoxic effect of olive mill waste extracts was evaluated using the 
MTT assay (methyl tetrazolium test). The IC
50
 values ranged from 4.8 to 7.6 μg/ml (Table 7), 
which demonstrate an effective cytoxicity of these phenolic compounds at low doses. We have 
demonstrated that the cytotoxic potential of these phenolic extracts was exhibited via apop-
tosis induction by DNA fragmentation test using agarose gel electrophoresis (Figure 4A). 
DNA isolated from MCF7 tumor cells was treated with OMW extracts at concentrations cor-
responding to the IC
50
 values and incubated for 24 h. To confirm the cell-death mechanism 
of these natural extracts, the apoptosis analysis was performed using the Annexin V biotin-
streptavidin FITC test. We reported that phenolic extracts induced significantly apoptosis 
(Figure 4B) compared to untreated cells (Figure 4C). Interestingly, those polyphenols have 
not shown any cytotoxic effect against human normal cells (PBMC) (Figure 5). Hence, it trig-
gered apoptosis in a dose-dependent manner on a breast cancer cell line (MCF-7) without any 
effects on normal cells by enhancing the viability with 12–16% in 48 h, compared to metho-
trexate (conventional cytotoxic drug), which suppressed 20%  viability of these cells.
Taken together, these data showed the differential and selective cytotoxic effect of natural 
polyphenols. In this sense, Miccadei et al. [43] have shown that polyphenolic extracts from 
the edible part of artichoke (Cynara scolymus L) may selectively inhibit the growth of human 
hepatoma cells with little or no toxicity against normal hepatocytes cells based on their dif-
ferential redox status. Interestingly, the authors have shown that Artichoke extracts exhibit 
a pro- oxidant activity in breast cancer cells and an antioxidant effect on normal hepatocytes. 
Moreover, some flavanols may have a significant effect on cytokine release from both unstim-
ulated and lipopolysaccharides-stimulated PBMCs [62]. Oral administration of naringenin 
suppressed breast cancer metastases after surgery by modulating the host immunity [63].
2.2.2.2. Role of polyphenols in therapy-induced senescence
Cellular senescence is a physiological process of irreversible cell-cycle arrest that contributes 
to various physiological and pathological processes of aging. It is an alternative and a novel 
Samples S1 S2 S3 S4 S5
IC
50
 (μg/ml) 6.95 ± 0.15 5.3 ± 0.1 4.75 ± 0.05 7.75 ± 0.15 5.3 ± 0.2
Table 7. IC
50
 values of the cytotoxicity of OMW polyphenolic extracts against MCF-7 breast cancer cell line.
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 therapeutic strategy to the cytotoxic treatment which leading to cytostasis approach target for 
aging and aging-related diseases [64]. Although senescence cells have irreversibly lost their 
capacity for cell division, they are still viable and remain metabolically active [65]. Prosenescence 
is usually associated with telomere erosion after repeated cell divisions and occurs in response to 
abnormal oncogenic signaling, oxidative stress, and DNA damage [66]. To this purpose, natural 
compounds targeting the epigenetic control of senescence are under investigations to develop 
additional prosenescence cancer therapeutic strategies [67]. Several anticancer polyphenolic 
compounds from fruit and vegetables have been shown to be potential chemopreventive and 
anticancer bioactive compounds [68] to induce cellular growth arrest through the induction of 
a ROS-dependent premature senescence. Among them, 20(S)-ginsenoside Rg3, a compound 
extracted from ginseng, and bisdemethoxycurcumin, a natural derivative of curcumin, caused 
senescence-like growth arrest and increased ROS production, respectively, in human glioma 
Figure 4. Apoptosis-induction analysis in MCF-7 cell line. (A) Phenolic extracts induced DNA fragmentation was 
detected by agarose gel electrophoresis of DNA isolated from MCF-7 tumor cells. Cells were incubated for 24 h with 
OCE (corresponding to IC
50
 concentrations). S1 to S5: Olive mill waste extracts samples. Positive control (WM): DNA 
weight marker. DNA of untreated cells was used as negative control (NC). (B) Annexin V biotin-streptavidin FITC test. 
MCF-7 tumor cells (2 × 106 cells) were treated with 25 μg/ml of OCE and incubated for 24 h. The assay is based on the 
ability of Annexin V (green fluorescence) to bind to the phosphatidylserine exposed on the surface of cells undergoing 
apoptosis. Cells cultured in a medium without serum were used as a positive control (C).
Figure 5. Cytotoxic effect of OMW polyphenolic extracts on normal human peripheral blood mono mononuclear cells 
(PBMC) from normal donors.
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cells [69] (and human breast cancer cell [70]. Therefore, high doses of polyphenolic extracts 
from artichoke may induce apoptosis and decrease cell proliferation of the human breast cancer 
cell line, MDA-MB231 via the induction of premature senescence through epigenetic and ROS-
mediated mechanisms [71]. Importantly, the authors have shown that Artichoke extracts have a 
pro-oxidant activity in breast cancer cells [72] and an antioxidant effect on normal hepatocytes 
[43]. Therefore, it has been hypothesized that Polyphenolic artichoke extracts could selectively 
inhibit the tumor cells growth with no cytotoxicity on healthy cells related on their differential 
cellular redox status. Furthermore, treatment with a low dose of resveratrol exhibits its chemo-
preventive and anticancer activities by induction of premature senescence in lung cancer cells. 
This event is associated with an increase in ROS generation and DNA double strands break 
through the up-regulation of NAPDH oxidase-5 expression [73]. The inhibitory effect of resvera-
trol was verified in vitro and in vivo, respectively, on gastric cells cancer and nude mice xenograft 
model. Low doses of resveratrol treatment arrested gastric cancer cells in the G1 phase and led 
to senescence instead of apoptosis and exerted inhibitory effect on gastric development and sig-
nificantly decreased the fraction of Ki67-positive cells in the nude mice tumor specimens [74]. 
Interestingly, Resveratrol and quercetin administers in subapoptotic doses can induce senes-
cence-like growth arrest in glioma tumors treatment [75]. The concept of prosenescence therapy 
has emerged over the past few years as a novel therapeutic approach to treat cancers, which may 
be viewed either as an independent anticancer approach or as a combined strategy with con-
ventional chemo/radiotherapy [76]. In a neoadjuvant setting, prosenescence therapy could be 
also used with traditional treatments in order to reduce tumor mass before surgery; whereas in 
adjuvant therapy, the engagement of prosenescence could be helpful in reducing the statistical 
risk of cancer relapse [77]. Although the effective potential of polyphenol in anticancer therapy 
as well as their other various beneficial effects on human health, the poor bioavailibility of these 
active ingredients still a pending issue which limits their potential effects and their incorporation 
on western medicine. Further aimed challenging studies are needed to improve the absorption, 
distribution, and metabolism in order to develop the in vivo use and in clinical interventions.
2.2.3. Artemisinin: a cytotoxic molecule with medical interests
Artemisinin, the active component of Qinghao (Chinese name of Artemisia annua L.) was dis-
covered in 1972 by Professor Tu’s team [78], a discovery that was recognized by her receipt of 
the Nobel Prize in medicine in 2015. Artemisinin belongs to the family of sesquiterpene lac-
tone with an endoperoxide bridge found to be important for its activity. The yield of artemis-
inin that can be extracted from Artemisia annua ranges from 0.01 and 0.8% of the dry weight 
[79]. This amount of extraction represents a serious limitation on the drug commercialization. 
Consequently, genetic engineering techniques have been used with the aim to improve the 
production of artemisinin in cell plant cultures and in transgenic plants as well.
2.2.3.1. In vitro cytotoxic properties of artemisinin
A significant cytotoxicity of artemisinin against tumors has been recently documented. It sug-
gests that artemisinin, commonly used against malaria, can be used to prevent and treat can-
cer [80–83]. It is a relatively safe drug, with known pharmacokinetics and pharmacodynamics 
studies. In fact, in vitro work on the effects of artemisinin, at different concentrations, shows 
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that artemisinin significantly inhibited growth and colony formation of human hepatocellu-
lar carcinoma cells through inducing apoptosis pathway [84]. Artemisinin at 20 μmol/l for 24 
or 48 h of exposure inhibits growth and cell viability of human ovarian carcinoma cell lines 
(OVCAR-432 and SK-OV-3) [85]. Moreover, a recent study from our laboratory demonstrated 
that artemisinin has a differential effect on cancer cells. In fact, artemisinin induced lysis on the 
murin mastocytoma cancer cell line (P815) with IC
50
 = 12 μM and on kidney adeno-carcinoma 
cell line of hamster with IC
50
 = 52μM [86]. Furthermore, artemisinin was described to possess an 
anticancer effect on breast, lung, prostate, colon, leukemia, and other cancer cell types. Despite 
its efficacy, artemisinin has pharmacokinetic limitations such as poor bioavailability and low 
solubility in water or oil [87]. Thus, it was developed with semi-synthetic derivatives drugs 
to overcome some of these problems. So far, semi-synthetic derivative of artemisinin such as 
artesunate and dihydroartemisinin have been demonstrated to exert an important in vitro anti-
cancer activity against different cancer cell lines. In breast cancer cells (MCF-7), artemisinin is 
less active, and the activity in these cells can be estrogen receptors-mediated (ERβ and ERα) 
which are implicated in cell proliferation [88]. In metastatic nasopharyngeal carcinoma cell 
lines (CNE-2 and CNE-1), the less sensitivity to artemisinin seems to be related to the over 
expression of polycomb complex protein BMI-1 [89]. Previously, Efferth et al. described a pro-
found cytotoxic activity of artesunate, a semi-synthetic derivative of artemisinin, against 55 
cancer cell lines of the U.S. National Cancer Institute with IC
50
 ranged from 246 nM to 100 μmM, 
by activating the expression of CDC25A and EGFR genes in cancer cells [83]. Another study 
by Efferth et al. showed that artesunate cytotoxicity on isogenic Saccharomyces cerevisiae with 
defined genetic defects, involved the implication of two putative target genes, BUB3 and CLN2 
[82]. Furthermore, it was described that the anticancer activity of artesunate, arteether, and arte-
mether (semi-synthetic derivative of artemisinin) is associated with the basal mRNA expression 
of 464 genes linked to proliferation of cells [90]. Generally, artemisinin molecules have been 
described to be more cytotoxic against cancer than normal healthy cells [86, 91], since normal 
cells contain significantly less free iron than cancer cells. In general, cancer cells, express more 
cell surface transferrin receptors and uptake significantly more iron than do normal cells [91].
Several studies have tried to explain, at molecular level, the mechanism of its anti-cancer 
action. A study on HL-60 cancer cell line demonstrated that rapid production of reactive oxy-
gen species is associated with cell death by apoptosis after artemisinin treated cells [92]. Other 
factors such as endoplasmic reticulum stress and calcium metabolism can also be associated 
with the anticancer activity of artemisinins [93, 94]. Endoplasmic reticulum seems to be a pos-
sible site for artemisinin action, in HepG2 cancer cell line a derivative fluorescence accumu-
lates preferentially in the endoplasmic reticulum as described by Crespo et al. [95].
Artemisinin has been described to induce apoptosis effect [86, 96, 97], as well as cell cycle 
arrest, especially at G0/G1 cell cycle transition phase [89, 98]. Multiple lines of evidence 
suggest that the apoptotic pathway could be due to intra and/or extra-mitochondrial mode 
of action, and the involvements of iron/heme as well [81, 99]. Two mechanistic pathways 
have been frequently described to explain the apoptotic effect of artemisinin, vascular endo-
thelial growth factor decrease [100–102], and nuclear factor-kappa B inhibition [103, 104]. 
Recently, other processes have also been illustrated in different cancer cell types, by the 
involvement of NOXA [105], mitogen-activated protein kinase (MAPK) [106], Wnt/β-catenin 
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[107], surviving [108], COX [109], c-MYC oncoprotein [93, 110], and epidermal growth fac-
tor [111]. Furthermore, it was also reported that the sensitivity to artemisinin action was 
related to the expression level of proapoptotic (Bax) and antiapoptotic (Bcl2) genes [112]. 
Also, artemisinin role in the inhibition of cancer is postulated to be associated with direct 
DNA damage [113] or indirectly in tumor cells involving a cascade of signaling pathways 
in many hallmarks of cancer [114]. Taken together, these results could explain the apoptotic 
pathway induction by artemisinin on tested cancer cells [101, 102, 115, 116]. However, we 
have also reported the possibility of the involvement of another cell death process of arte-
misinin; probably necrosis [86]. Artemsinin-induced necrosis remains not well documented 
and may be linked with the increasing level of ATP, defective apoptotic pathways, reactive 
oxygen species-independent mechanism of programmed cell death and cancer cell line type 
[86]. Furthermore, we have described that artemisinin interacted synergistically and addi-
tively with vincristin to reduce cancer cell proliferation [86], suggesting a possible use of 
artemisinin as an adjuvant to treat cancer.
2.2.3.2. In vivo anti-tumor and antimetastatic effects
Artemisinin treatment in oral route at 80 mg/kg considerably reduced the tumor volume 
growth of P815/DBA2 mice as described by our team [86]. In HepG2 and Hep3B human 
hepatoma mouse xenograft, artemisinin administered at 50 or 100 mg/kg/day delayed tumor 
onset, respectively, by 30 and 39.4% [117]. Also, in another study, artemisinin reduced tumor 
growth at 50% on day 20, when injected intraperitoneally at a concentration of 2.8 mg/kg/
day on mammary gland ductal carcinoma in mice [118]. Inhibition of tumor growth and anti-
angiogenic effect in MCF-7 mouse xenograft after subcutaneous treatment with artemisinin 
at dose 100 mg/kg/day for 2 weeks was reported [98]. Interestingly, artemisinin exhibited an 
anti-metastatic effect [116]. In fact, these authors showed that after orally artemisinin treat-
ment with 50 mg/kg, a reduction of 63.5% of lung metastasis and lymph node metastases 
decrease in cervical and mediastinal lymph nodes, as well as an inhibition of lymphangio-
genesis by 63% of mice. Artemisinin also exhibited inhibitory effects in lung tumor metastasis 
by 51.8 and 79.6% for 50 and 100 mg/kg/day, respectively. Furthermore, it was described 
that artesunate given in the drinking water at 167 mg/kg/day suppressed growth of Kaposi’s 
sarcoma-IMM xenograft tumors in nude mice [119]. The antimetastatic effect of artemisinin 
seems to be associated with the expression of metalloproteinase genes and their effect on 
αvβ3 integrins [120]. Moreover, the decrease of MMP2 with an increase of TIMP-2 in HepG2 
and SMMC772 cancer cell lines after artemsinin treatment were reported [121]. Interestingly, 
the antimetastatic effect of artemisinin could be triggered by enhancing Cdc42 and E-cadherin 
activation [121]. However, in highly metastatic cancer such as nasopharyngeal cancer (CNE-
1,CNE-2 cancer cell lines), artemisinin seems to have a low response due to the overexpression 
of BMI-1 gene that makes these cancer cells more sensitive to artemisinin drug [122]. In highly 
metastatic MDA-MB-231 breast tumor cells, artesunate induced resistance as described by 
Beatrice Bachmeier et al. (2011). This resistance was induced by the activation of transcrip-
tion factors NF-κB and AP-1 [123]. Another study showed suppression of invasive and meta-
static non-small cell lung cancer after artesunate treatment by the inhibition of urokinase-type 
plasminogen activator (u-PA), and matrix metalloproteinases (especially MMP-2 and MMP-7) 
transcription [10].
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3. Conclusion
Nature continues to produce a great wealth of natural molecules endowed with cytotoxic 
activity towards a large panel of tumor cells. More than 60% of these molecules such as vin-
blastine, vincristine, etoposide, teniposide, taxol, navelbine, and camptothecin are used in 
chemotherapy and others have shown great anti-tumor and anti-metastatic potential in pre-
clinical trials [124, 125]. Other natural product (i.e., Romidepsin 14, Omacetaxine mepesuccinate) 
[126] and natural product-derived drugs (i.e., metformin, metformin Polyphenon E, retinoids, 
soy isoflavones) [127] are in clinical trials. This chapter discusses some examples of these 
molecules (carvacrol, thymol, carveol, carvone, eugenol, isopulegol, and artemisinin) as well 
as polyphenols extract that have been studied in our laboratory. Other natural compounds 
are also under studies and remain promising. It is clear that if we understand the molecular 
mechanisms of the various interactions between these cytotoxic molecules on the one hand 
and the tumor cells in their tumoral environments on the other hand, we can develop new 
therapeutic modalities to overcome the side effects of these molecules and to fight cancer.
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